BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31045648)

  • 1. Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV.
    van Zoest RA; Law M; Sabin CA; Vaartjes I; van der Valk M; Arends JE; Reiss P; Wit FW
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):562-571. PubMed ID: 31045648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study.
    Thompson-Paul AM; Lichtenstein KA; Armon C; Palella FJ; Skarbinski J; Chmiel JS; Hart R; Wei SC; Loustalot F; Brooks JT; Buchacz K
    Clin Infect Dis; 2016 Dec; 63(11):1508-1516. PubMed ID: 27613562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models.
    Krikke M; Hoogeveen RC; Hoepelman AI; Visseren FL; Arends JE
    HIV Med; 2016 Apr; 17(4):289-97. PubMed ID: 26268806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection.
    Triant VA; Perez J; Regan S; Massaro JM; Meigs JB; Grinspoon SK; D'Agostino RB
    Circulation; 2018 May; 137(21):2203-2214. PubMed ID: 29444987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.
    Friis-Møller N; Ryom L; Smith C; Weber R; Reiss P; Dabis F; De Wit S; Monforte AD; Kirk O; Fontas E; Sabin C; Phillips A; Lundgren J; Law M;
    Eur J Prev Cardiol; 2016 Jan; 23(2):214-23. PubMed ID: 25882821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis.
    Soares C; Kwok M; Boucher KA; Haji M; Echouffo-Tcheugui JB; Longenecker CT; Bloomfield GS; Ross D; Jutkowtiz E; Sullivan JL; Rudolph JL; Wu WC; Erqou S
    JAMA Cardiol; 2023 Feb; 8(2):139-149. PubMed ID: 36576812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations.
    Achhra AC; Lyass A; Borowsky L; Bogorodskaya M; Plutzky J; Massaro JM; D'Agostino RB; Triant VA
    Curr HIV/AIDS Rep; 2021 Aug; 18(4):271-279. PubMed ID: 34247329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.
    Guo F; Hsieh E; Lv W; Han Y; Xie J; Li Y; Song X; Li T
    BMC Infect Dis; 2017 Apr; 17(1):287. PubMed ID: 28427339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Framingham risk score based vascular outcomes in acute versus chronic HIV cohorts after 6 years of ART.
    Holroyd KB; Han WM; Apornpong T; Trautmann L; Gatechompol S; Hiransuthikul A; Ubolyam S; Sacdalan C; Sriplienchan S; Kanaprach R; Kerr S; Avihingsanon A; Spudich S; Chan P
    HIV Med; 2024 Jun; 25(6):725-736. PubMed ID: 38383057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in Taiwan.
    Wu PY; Chen MY; Sheng WH; Hsieh SM; Chuang YC; Cheng A; Pan SC; Wu UI; Chang HY; Luo YZ; Yang SP; Zhang JY; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2019 Aug; 52(4):549-555. PubMed ID: 31036484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction models for cardiovascular disease risk among people living with HIV: A systematic review and meta-analysis.
    Yu J; Liu X; Zhu Z; Yang Z; He J; Zhang L; Lu H
    Front Cardiovasc Med; 2023; 10():1138234. PubMed ID: 37034346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of Subclinical Vascular Damage in People Living With HIV Is Not Predicted by Current Cardiovascular Risk Scores: A Prospective 3-Year Study.
    Kapelios CJ; Argyris AA; Protogerou AD; Katsarolis I; Arida A; Papadopoulou M; Ntaroutsou E; Kitas G; Sfikakis PP; Psichogiou M
    J Acquir Immune Defic Syndr; 2020 Apr; 83(5):504-512. PubMed ID: 31923089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traditional Cardiovascular Risk Factors Strongly Underestimate the 5-Year Occurrence of Cardiovascular Morbidity and Mortality in Spinal Cord Injured Individuals.
    Barton TJ; Low DA; Bakker EA; Janssen T; de Groot S; van der Woude L; Thijssen DHJ
    Arch Phys Med Rehabil; 2021 Jan; 102(1):27-34. PubMed ID: 32861666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart.
    Chen L; Tonkin AM; Moon L; Mitchell P; Dobson A; Giles G; Hobbs M; Phillips PJ; Shaw JE; Simmons D; Simons LA; Fitzgerald AP; De Backer G; De Bacquer D
    Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):562-70. PubMed ID: 19741542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.
    Crowson CS; Gabriel SE; Semb AG; van Riel PLCM; Karpouzas G; Dessein PH; Hitchon C; Pascual-Ramos V; Kitas GD;
    Rheumatology (Oxford); 2017 Jul; 56(7):1102-1110. PubMed ID: 28339992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Level of agreement between frequently used cardiovascular risk calculators in people living with HIV.
    Dhillon S; Sabin CA; Alagaratnam J; Bagkeris E; Post FA; Boffito M; Anderson J; Vera J; Williams I; Johnson M; Sachikonye M; Babalis D; Mallon PW; Winston A;
    HIV Med; 2019 May; 20(5):347-352. PubMed ID: 30873751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of the American Heart Association/American College of Cardiology Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Self-reported Physical Activity Levels.
    Pandey A; Mehta A; Paluch A; Ning H; Carnethon MR; Allen NB; Michos ED; Berry JD; Lloyd-Jones DM; Wilkins JT
    JAMA Cardiol; 2021 Jun; 6(6):690-696. PubMed ID: 33909016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV-HEART Study compared with the general population.
    Schulz CA; Mavarani L; Reinsch N; Albayrak-Rena S; Potthoff A; Brockmeyer N; Hower M; Erbel R; Jöckel KH; Schmidt B; Esser S;
    HIV Med; 2021 Sep; 22(8):732-741. PubMed ID: 34028959
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.